TX HB3265

Prohibits drug manufacturers, distributors, and logistics providers from discriminating against 340B covered entities or their contract pharmacies, including denying, restricting, or limiting acquisition or delivery of 340B drugs

Bars manufacturers from requiring covered entities to submit claim or utilization data as a condition for acquiring 340B drugs, except for federally-mandated reporting or compliance audits conducted under HHS procedures

Prohibits health benefit plan issuers, pharmacy benefit managers, and third-party payors from reimbursing 340B entities at lower rates than non-covered entities, imposing differential fees or network restrictions, or requiring 340B drug identifiers on claims

Violations constitute deceptive trade practices with civil penalties up to $50,000 per package of 340B drugs affected; complaints investigated by the department and referred to the attorney general

Applies to health benefit plans delivered or renewed on or after January 1, 2026, and to prescription drugs manufactured on or after September 1, 2025; does not create a private cause of action